CMMB logo

CHEMOMAB THERAPEUTICS LTD

CMMBNASDAQ
🏆 #4932 by market capEarnings Nov 18US Equity
$1.10▲ $0.05 (+4.76%)
Market closed · at close
🔔
Track CMMB
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 4.8%
7d▲ 4.8%
14d▼ 15.1%
30d▼ 31.7%
ytd▼ 32.9%
1y▼ 64.1%
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.10 – $1.15
52-Week Range
$0.92 – $3.29
Volume (shares)
21,849
Avg Volume (shares)
—
Shares Outstanding
6.2M
Next Earnings
2026-11-18

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-1.1
P/S Ratio
0.0x
EPS (TTM)
$-0.95
Dividend Yield
0.00%
Dilution (1yr)
+65.9%
CMMB logo

CHEMOMAB THERAPEUTICS LTD

CMMB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$10M▼ −35.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▼ −27.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
7.8M▲ +65.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▲ +$2M YoY
StockOtter · stockotter.space

About CHEMOMAB THERAPEUTICS LTD

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWire·Aug 31

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high u

GlobeNewsWire·Aug 19

Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Planned merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in RA continues to advance with closing expected by year-end